title: Antagonism between gene therapy and epigenetic therapy on human laryngeal carcinoma tumor-bearing mice.
abstract: BACKGROUND
  Gene therapy and epigenetic therapy have gained more attention in cancer treatment. However, the effect of a combined treatment of gene therapy and epigenetic therapy on head and neck squamous cell carcinoma have not been studied yet. To study the mechanism and clinical application, human laryngeal carcinoma cell (Hep-2) tumor-bearing mice were used.
  
  
  METHODS
  A xenograft tumor model was established by the subcutaneous inoculation of Hep-2 cells in the right armpit of BALB/c nu/nu mice. The mice with well-formed tumor were randomly divided into six groups. Multisite injections of rAd-p53 and/or 5-aza-dC were used to treat tumor. Tumor growth was monitored by measuring tumor volume and growth rate. p53 and E-cadherin protein levels in tumor tissues were detected by immunohistochemical staining. The mRNA levels were monitored with FQ-PCR.
  
  
  RESULTS
  Gene therapy was much more effective than single epigenetic therapy and combined therapy. The gene therapy group has the lowest tumor growth rate and the highest expression levels of p53 and E-cadherin.
  
  
  CONCLUSIONS
  The combined treatment of gene and epigenetic therapy is not suggested for treating head and neck carcinoma, because gene therapy shows an antagonistic effect to epigenetic therapy. However, the mechanisms of action are still unclear.
authors: Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors: Meng
authors: M
authors: Lian
authors: Qi
authors: Q
authors: Wang
authors: Ju-Gao
authors: JG
authors: Fang
authors: Hong
authors: H
authors: Wang
authors: Er-Zhong
authors: EZ
authors: Fan
mesh_terms: D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015820:Cadherins / Q000032:analysis; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D044127:Epigenesis, Genetic; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D023041:Xenograft Model Antitumor Assays
chemical_list: D015820:Cadherins; D016159:Tumor Suppressor Protein p53; D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine